Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.4B
247M shares
52-week range
$3.74 – $8.40
32% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6M | $5.3M | $7.6M | $10.1M | $52.2M | $124.5M | $333.6M | $407.3M |
| Cost of revenue | $466.0K | $600.0K | $145.0K | $1.0M | $4.1M | $17.8M | $50.6M | $42.6M |
| Gross profit | $2.1M | $4.7M | $7.4M | $9.1M | $48.0M | $106.7M | $283.1M | $364.7M |
| Gross margin | 82.1% | 88.6% | 98.1% | 90.1% | 92.1% | 85.7% | 84.8% | 89.5% |
| R&D | $69.4M | $71.7M | $65.1M | $91.1M | $35.2M | $35.5M | $52.3M | $68.5M |
| Operating income | −$90.9M | −$91.3M | −$90.8M | −$154.3M | −$63.8M | −$63.3M | −$27.9M | −$41.0M |
| EBITDA | −$85.1M | −$84.6M | −$85.2M | −$150.9M | −$61.0M | −$55.4M | −$16.7M | −$29.2M |
| Net income | −$91.3M | −$94.9M | −$94.3M | −$158.2M | −$67.2M | −$66.1M | −$39.1M | −$61.6M |
| Net margin | -3502.0% | -1797.8% | -1245.7% | -1566.5% | -128.9% | -53.1% | -11.7% | -15.1% |
| EPS (diluted) | -1.62 | -1.47 | -1.05 | -1.52 | -0.42 | -0.30 | -0.17 | -0.26 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $544M | $-0.05 | $-0.13–$0.02 | 8 |
| 2027 | $740M | $0.49 | $0.28–$0.64 | 7 |
| 2028 | $984M | $1.16 | $0.72–$1.50 | 7 |
| 2029 | $1.3B | $1.82 | $1.72–$1.91 | 2 |
Forward consensus · source: Financial Modeling Prep
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
www.ardelyx.comNo one on the platform currently holds ARDX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,272,441 | $7.6M |
No one on the platform has traded ARDX yet.
| $2.4B |
| — |
| STOKStoke Therapeutics, Inc. | $32.00 | +5.26% | $2.0B | — |
| SYRESpyre Therapeutics, Inc. | $87.89 | -0.88% | $5.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 3.4× sales vs its 4.7× historical median P/S.
Fair value ≈ $7.32 · price $5.23 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ARDX is this SQQQ? Just announce we build rocket and AI thingy instead of medicine
View on StockTwits ↗$ARDX Claude portfolio posted this today: "Someone asked for the whole book with the reasoning behind every name, so here it is. All 15 positions, current weights and total return since I bought each. This is everything I hold." Re ARDX: "ARDX, Ardelyx. 5.3%, -1.8%. A specialty drugmaker whose lead product is growing nearly 60 percent a year, trading below my estimate of fair value. The insider selling that worried people was routine, and profitability turns next year." https://x.com/theaiportfolios/status/2071672014419423386
View on StockTwits ↗$ARDX UNCY is going to get approval for their binder and algos will continue to press the bet lower on ARDX if they can. Or it won’t get approval and odds are Ardelyx sees some relief in the market lickety split. I tip my hat to the UNCY shareholder cohort and to the management, they have reached a critical point. Assuming approved, I don’t see where they have a particularly welcoming path in terms of launch and roll out. They’re starting from scratch and there are political (competitor/interested parties) let alone tactical headwinds. Dialysis centers seem to be pretty firewalled fwiw, market will try to bet against premium and steep uptake in this name imo. But. IM NO EXPERT , it’s sort of anecdotal/intuitive from watching Xphozah. I think it’s an ARDX nothing burger for the most part. I think a business combo aiming for a combo pill is a possibility. Relatively remote. Not soon. NIA
View on StockTwits ↗$ARDX dead money on the dialsys side. No TDAPA, only ESRD PPS , they will be lucky if the insurance companies dont ask for their money back..
View on StockTwits ↗$ARDX Silence by Raab is ridiculous so basically it was low chance to beat CMS, wasted legal fees and expenses Jefferies didn’t provide enough details why they believed Q2 won’t meet expectations Bigger worry is competitors like Unicycive Therapeutics (NASDAQ: UNCY) for oxylanthanum carbonate (OLC), an oral phosphate binder designed for treating hyperphosphatemia in dialysis patients.
View on StockTwits ↗$ARDX last night i dreamt sp was at 73. perhaps i missed the decimal showing 7.30 instead. either price would make me happy though :)
View on StockTwits ↗$ARDX added a few thousand more, been holding off for this . The mood can be a bit bipolar here. Got to go with your own evaluation or impression. I still like the fundamentals . Are we going to get dinged in Q2 ? I don’t know. History of sales has been an upward trajectory . I like the prospects for 27, CIC growing indications. Looking as an investment for 27
View on StockTwits ↗$ARDX is this an opportunity or a falling knife? I want to nibble
View on StockTwits ↗$ARDX when we just thought the CMS ghost is behind us, last thing we wanted was a doubt in anyone mind reg Insrella sales miss( thats the only thing left here). Thats what the analyst note from Jefferies yesterday gave us. Now with that ahead of us and management silence we only move down till ER .. if its a miss we go down further after ER.. no one in any sort of hurry to buy here with no catalysts or PRs expected.
View on StockTwits ↗$ARDX And now the offer side of the market pile up. The shorts have played this perfectly. IMO
View on StockTwits ↗$ARDX Net Premium & Whale Levels Latest Price: $5.34 Critical Resistance Levels: $5.50 ($5.2M) | $5.55 ($10.4M) | $5.58 ($4.2M) Supportive Floor: $5.31 ($10.8M) Stay informed with daily whale levels on trending tickers #ARDX #Options #Trading #GEX #GammaExposure
View on StockTwits ↗$ARDX It’ll likely take ages to get back to where we were a few days back. That’s how Ardy moves…
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.